Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
|
|
- Branden Lindsey
- 5 years ago
- Views:
Transcription
1 Ann. N.Y. Acad. Sci. ISSN ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: Pharmaceutical Science to Improve the Human Condition: Prix Galien 2014 Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus Norm Rosenthal, 1 Gary Meininger, 1 Kirk Ways, 1 David Polidori, 2 Mehul Desai, 1 Rong Qiu, 1 Maria Alba, 1 Frank Vercruysse, 1 Dainius Balis, 1 Wayne Shaw, 1 Robert Edwards, 1 Scott Bull, 3 Nicholas Di Prospero, 1 Sue Sha, 1 Paul Rothenberg, 1 William Canovatchel, 1 and Keith Demarest 1 1 Janssen Research & Development, LLC, Raritan, New Jersey. 2 Janssen Research & Development, LLC, San Diego, California. 3 Janssen Research & Development, LLC, Fremont, California Address for correspondence: Norm Rosenthal, Janssen Research & Development, LLC, 920 Route 202 South, Raritan, NJ NRosenth@its.jnj.com The sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin is a novel treatment option for adults with type 2 diabetes mellitus (T2DM). In patients with hyperglycemia, SGLT2 inhibition lowers plasma glucose levels by reducing the renal threshold for glucose (RT G ) and increasing urinary glucose excretion (UGE). Increased UGE is also associated with a mild osmotic diuresis and net caloric loss, which can lead to reductions in body weight and blood pressure (BP). After promising results from preclinical and phase I/II studies, the efficacy and safety of canagliflozin was evaluated in a comprehensive phase III development program in over 10,000 patients with T2DM on various background therapies. Canagliflozin improved glycemic control and provided reductions in body weight and BP versus placebo and active comparators in studies of up to 2 years duration. Canagliflozin was generally well tolerated, with higher incidences of adverse events (AEs) related to the mechanism of action, including genital mycotic infections and AEs related to osmotic diuresis. Results from the preclinical and clinical studies led canagliflozin to be the first-in-class SGLT2 inhibitor approved in the United States, and support canagliflozin as a safe and effective therapeutic option across a broad range of patients with T2DM. Keywords: SGLT2 inhibitor; antihyperglycemic agent; canagliflozin; type 2 diabetes Introduction Type 2 diabetes mellitus (T2DM) is well recognized as a major public health problem worldwide. 1 3 Despite the availability of a range of therapeutic options, many patients with T2DM do not achieve or maintain glycemic goals as recommended by international medical societies. 4 Many of the currently available T2DM treatments are associated with safety or tolerability issues, including hypoglycemia, edema, or gastrointestinal adverse experiences, which can preclude their use in some patients or limit dose and, hence, therapeutic benefit. 4 6 Further, some antihyperglycemic agents (AHAs) are associated with weight gain, which is particularly problematic as many patients with T2DM are overweight or obese. 4,5 Most patients with T2DM are initially managed with single-agent therapy, usually metformin. 4,7 Over time, patients often require more intensive regimen combinations of two or three agents and eventually require insulin to maintain target glycemic control. 4,8,9 Underlying this need for increasingly intensive treatment is a progressive loss of beta-cell mass and function, with consequent diminished insulin secretion. Thus, there remains a substantial unmet medical need for new medications to treat patients with T2DM that beneficially impact beta-cell function and insulin secretion, and are associated with weight loss, which improves insulin sensitivity. In healthy individuals, circulating glucose is freely filtered through the renal glomerulus, reabsorbed doi: /nyas Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
2 Rosenthal et al. Canagliflozin for the treatment of type 2 diabetes Figure 1. The role of SGLT2 in glucose reabsorption in the renal proximal tubule. 12,13 SGLT, sodium glucose co-transporter; GLUT, glucose transporter. Figure 1 reprinted from Trends in Pharmacological Sciences 32(2): 63 71, Copyright (2011), with permission from Elsevier; and Current Medical Research and Opinion 25(3): , Copyright (2009), Informa Healthcare, adapted with permission from Informa Healthcare. in the proximal tubule, and then released back into the circulation. The renal threshold for glucose (RT G ) is the plasma glucose concentration above which tubular reabsorption of glucose cannot increase further, and glucose is excreted into the urine in direct proportion to the plasma glucose concentration above this threshold. Glucose reabsorption in the renal tubules is largely due to two key glucose transporters: sodium glucose co-transporter 2 (SGLT2), responsible for the majority of filtered glucose reabsorption in the S1 segment of the proximal renal tubules, and SGLT1, responsible for glucose reabsorption in the S2/S3 segment of the proximal renal tubules (Fig. 1) Patients with diabetes have elevated renal glucose reabsorption mostly due to the increased expression Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences 29
3 Canagliflozin for the treatment of type 2 diabetes Rosenthal et al. Figure 2. Inhibition of SGLT2 by canagliflozin leads to increased renal glucose excretion and improved glucose homeostasis. 18 SGLT2, sodium glucose co-transporter 2; UGE, urinary glucose excretion; RT G, renal threshold for glucose; T2DM, type 2 diabetes mellitus; CANA, canagliflozin. Adapted from Metabolism 63(10): (2014), under the terms of the Creative Commons Attribution License, of SGLT2, 14 which may contribute to persistent elevated glucose concentrations 15 and to diabetic nephropathy. 16 Canagliflozin (INVOKANA R ) was the first SGLT2 inhibitor available in the United States. It is currently approved as an adjunct to diet and exercise to lower blood glucose in adults with T2DM. AlargenumberofcountriesacrossNorthAmerica, Europe, Latin America, and Asia-Pacific have approved canagliflozin for the treatment of adults with T2DM. Other SGLT2 inhibitors approved to treat T2DM include dapagliflozin, empagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin. Only canagliflozin, dapagliflozin, and empagliflozin are approved for use in the United States and Europe. 17 Pharmacologic inhibition of SGLT2 is a novel mechanism to reduce reabsorption of filtered glucose and lower the RT G (Fig. 2), 18 thereby increasing urinary glucose excretion (UGE) and lowering elevated plasma glucose concentrations in patients with T2DM. The increased UGE with SGLT2 inhibition also translates to an osmotic diuresis, with the diuretic effect offering the potential for reductions in systolic blood pressure (BP). In addition, increased UGE results in a loss of calories and, therefore, could lead to a reduction in body weight. This mechanism is independent of insulin secretion, and thus canagliflozin would be expected to be effective across the spectrum of beta-cell function, from new-onset patients with moderate impairment of beta-cell function, to patients with greater beta-cell functional loss, such as those with long-standing diabetes who require insulin. In addition, as this mechanism is distinct from other current classes of AHAs, canagliflozin has the potential for use in combination with a wide range of other agents in the treatment of patients with T2DM. Thus, canagliflozin is an insulin-independent approach for control of hyperglycemia and may be used across the continuum of the disease, providing glycemic efficacy in combination with a wide range of other glucose-lowering agents, as well as the additional benefits of weight loss and BP reduction. History of the discovery and development of canagliflozin The first known inhibitor of renal glucose reabsorption was phlorizin, a natural product isolated from the bark of apple trees. 19 Phlorizin was shown to cause glucosuria in dogs, and subsequent studies found that administration of phlorizin to diabetic rats reduced plasma glucose levels and improved insulin sensitivity. 19,20 However, phlorizin has not been developed for use in humans because it has poor oral bioavailability, modest SGLT2 inhibition, and its active metabolite phloretin inhibits facilitative glucose transporters. 19,21 The involvement of Janssen Research & Development in SGLT2 inhibitor development began as a collaboration with Mitsubishi Tanabe Pharma Corporation in August 2000 to develop T-1095, an orally available 30 Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences
4 Rosenthal et al. Canagliflozin for the treatment of type 2 diabetes Figure 3. Structural illustration of phlorizin, T-1095, and canagliflozin. SGLT, sodium glucose co-transporter; CYP, cytochrome P450. analogue of phlorizin. T-1095 selectively inhibits SGLT2 in vitro, increases UGE, and decreases fasting and prandial blood glucose levels in rodent models of diabetes. Clinical development of T-1095 began in May 2001 and included phase I and phase IIa proof-of-concept trials. T-1095 was well tolerated, but had a short half-life in humans, showed cytochrome P450 inhibition, and did not meaningfully lower blood glucose in patients with T2DM, despite promoting UGE. The failure of this key phase IIa trial cast significant doubt on SGLT2 inhibition as an effective mechanism for treating T2DM, and clinical development of T-1095 was terminated in January To understand why T-1095 lacked clinical efficacy, a new physiologically based model of human glucose homeostasis was developed, which included the role of renal glucose transport and incorporated SGLT2 inhibitor drug pharmacokinetics and pharmacodynamics (unpublished work). Insights from this modeling explained why the key phase IIa trial with T-1095 failed and, importantly, provided a clear rationale for expecting that meaningful glycemic efficacy in patients with T2DM might be obtained with an SGLT2 inhibitor drug that had appropriate pharmacokinetic and pharmacodynamic properties. The modeling effort also established quantitative criteria (based on 24-hour UGE in the first single oral-dose phase I trial of canagliflozin in healthy participants) for deciding whether any new SGLT2 inhibitor could, in principle, yield meaningful therapeutic efficacy in longer-duration trials in patients with T2DM. A collaborative effort was initiated to discover a replacement for T-1095 with improved potency and bioavailability, which resulted in the discovery of canagliflozin. The C-glycoside canagliflozin was significantly more stable and showed greater selectivity for SGLT2 than T Canagliflozin exhibited greatly improved bioavailability and efficacy in animal models of diabetes and entered phase I clinical development in December A structural illustration of phlorizin, T-1095, and canagliflozin is shown in Figure 3. Pharmacodynamics and pharmacokinetics of canagliflozin Canagliflozin is rapidly absorbed in humans, with an oral availability of 65%; peak plasma concentrations are reached within 1 2 hours. 22 The mean half-life of canagliflozin 100 and 300 mg in healthy individuals is 10.6 and 13.1 hours, respectively, which supports once-daily dosing. 23 Canagliflozin is glucuronidated by uridine diphosphate-glucuronosyltransferase (UGT) enzymes into two inactive O-glucuronide metabolites, M5 and M7. 24 Approximately 60% and 33% of the administered dose is excreted in the feces and urine, respectively. 24 Canagliflozin treatment dose-dependently lowered RT G, and maximally effective doses lowered RT G to approximately mg/dl in healthy individuals and mg/dl in patients with Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences 31
5 Canagliflozin for the treatment of type 2 diabetes Rosenthal et al. Figure 4. Overview of the canagliflozin phase III clinical program. AHA, antihyperglycemic agent; PBO, placebo; SITA, sitagliptin; MET, metformin; SU, sulfonylurea; GLIM, glimepiride; PIO, pioglitazone; CV, cardiovascular; CANVAS, CANagliflozin CardioVascular Assessment Study. T2DM Because RT G typically remains above the threshold for hypoglycemia (70 mg/dl) in patients with T2DM, and very little UGE occurs when plasma glucose levels are below RT G,treatment with canagliflozin is not expected to induce hypoglycemia. Canagliflozin 300 mg provided nearmaximal suppression of RT G over 24 h, while canagliflozin 100 mg provided near-maximal suppression of RT G for the first 13 h after dosing, with a slight attenuation of the effect in the overnight period. 26,27 In addition, higher canagliflozin doses (>200 mg) were found to lower plasma glucose levels to a greater extent than could be explained by UGE alone; this additional effect is likely due to transient inhibition of gastrointestinal SGLT1 during the period of drug absorption. 26 In addition to inhibiting SGLT2, canagliflozin is a low-potency inhibitor of SGLT1, which is highly expressed in the intestine and is largely responsible for intestinal glucose and galactose absorption. 30,31 Canagliflozin 300 mg, dosed just before a meal, delayed intestinal glucose absorption in healthy individuals; because free plasma drug concentrations were not high enough to inhibit renal SGLT1, it is believed that transiently high local concentrations of canagliflozin within the gut lumen results in transient and local inhibition of SGLT1 in the intestine. 31 Clinical development program for canagliflozin in adults with T2DM The canagliflozin clinical program was designed to assess its efficacy and safety in patients with T2DM. This program consisted of 52 completed or ongoing clinical studies, collecting data from 10,285 participants(whoreceivedatleastonedoseofdoubleblind study drug) in nine phase III studies, 1210 participants in three phase II studies, and 1300 participants in 40 phase I studies. The nine placebocontrolled and active comparator controlled (versus glimepiride and sitagliptin) phase III studies spanned a range of clinical uses (as monotherapy or as combination therapy) across a broad population of patients with T2DM, including older adults, patients with moderate renal impairment, and patients who had or were at high risk for cardiovascular (CV) disease (Fig. 4) Canagliflozin clinical development program results HbA 1c -lowering response Results of the phase III studies confirmed the efficacy of canagliflozin in reducing glycated hemoglobin (HbA 1c ) across a broad range of patients with T2DM, both in patients with recent 32 Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences
6 Rosenthal et al. Canagliflozin for the treatment of type 2 diabetes Figure 5. Study-by-study comparison of efficacy with canagliflozin: (A) change from baseline in HbA 1c, (B) proportion of patients achieving HbA 1c <7.0%, (C) percent change from baseline in body weight, and (D) change from baseline in SBP (LOCF). 32,34-36,38-40,42,44,63,a HbA 1c, glycated hemoglobin; SBP, systolic blood pressure; LOCF, last observation carried forward; PBO, placebo; CANA, canagliflozin; GLIM, glimepiride; SITA, sitagliptin; LS, least squares; SE, standard error; MET, metformin; SU, sulfonylurea; PIO, pioglitazone; CANVAS, CANagliflozin CardioVascular Assessment Study; SD, standard deviation. a Data are LS mean ± SE changes from baseline in HbA 1c (panel A), body weight (panel C), and SBP (panel D); and percentage ± SD achieving HbA 1c < 7.0% (panel B). b P < vs. PBO, GLIM, or SITA. c P < 0.05 vs. PBO. d Patients receiving 30 IU/day. e P < 0.01 vs. PBO. f P < vs. PBO. g Statistical comparison vs. GLIM not performed (not prespecified). Continued on next page. onset as well as long-standing diabetes and those on different background AHA therapies. A clinically meaningful improvement in glycemic control was seen when canagliflozin was given as monotherapy and in dual combinations (add-on to metformin or to sulfonylurea agents), triple oral AHA combinations (add-on to metformin plus a sulfonylurea agent or metformin plus pioglitazone), combinations with insulin (alone or with other oral agents), or as an add-on to existing diabetes therapy (any approved oral or parenteral therapy) In the placebo-controlled studies, canagliflozin Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences 33
7 Canagliflozin for the treatment of type 2 diabetes Rosenthal et al. Figure 5. Continued 100 and 300 mg provided statistically significant reductions in HbA 1c compared with placebo (Fig. 5A). In the active-controlled studies, canagliflozin 100 mg demonstrated noninferiority to sitagliptin and glimepiride in lowering HbA 1c, whereas canagliflozin 300 mg demonstrated statistical superiority to sitagliptin and glimepiride. Across all studies, an incremental HbA 1c reduction was observed for the 300 mg dose relative to the 100 mg dose. In addition, a greater proportion of patients treated with canagliflozin achieved the recommended treatment goal of HbA 1c <7.0% compared with those treated with placebo (Fig. 5B). Canagliflozin was also associated with sustained reductions in HbA 1c over 104 weeks compared with glimepiride as an add-on to metformin (Fig. 6A), demonstrating the durability of HbA 1c lowering with canagliflozin. 37 Given its mechanism of action, in which the extent of UGE is proportional to renal function, 34 Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences
8 Rosenthal et al. Canagliflozin for the treatment of type 2 diabetes Figure 6. Change in HbA 1c (A), percent change in body weight (B), and mean egfr (C) over 104 weeks in the add-on to metformin versus glimepiride study (DIA3009; LOCF). 37 Data in panels A and B are LS mean ± SE, and data in panel C are mean ± SE. HbA 1c, glycated hemoglobin; egfr, estimated glomerular filtration rate; LOCF, last observation carried forward; GLIM, glimepiride; CANA, canagliflozin; LS, least squares; CI, confidence interval; SE, standard error. Figure 6 reprinted from American Diabetes Association, Diabetes Care, Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association. Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences 35
9 Canagliflozin for the treatment of type 2 diabetes Rosenthal et al. it was anticipated that the efficacy of canagliflozin would be dependent on estimated glomerular filtration rate (egfr). A phase I study of canagliflozin in patients with renal impairment demonstrated that the amount of UGE declined as renal function decreased. 45 Therefore, it was important to determine whether adequate benefit would be retained in patients with moderate renal impairment. The phase III study in patients with moderate renal impairment (DIA3004) demonstrated meaningful and statistically significant glycemic efficacy of canagliflozin in patients with egfr 30 to <50 ml/min/1.73 m 2, even though the reductions in HbA 1c and fasting plasma glucose were smaller than those seen in patients with higher baseline egfr values. 43,44 These observations were confirmed and extended with a pooled population analysis of patients with baseline egfr 30 to <60 ml/min/1.73 m 2, consistent with the full range of stage 3 chronic kidney disease (CKD). 46 In this pooled population, the glycemic efficacy of canagliflozin was modestly greater than that observed in the DIA3004 study, consistent with the slightly higher mean and range of baseline egfr values in patients analyzed. Canagliflozin provided greater HbA 1c reductions in patients with stage 3A CKD (egfr 45 and <60 ml/min/1.73 m 2 ) than in patients with stage 3B CKD (egfr 30 and <45 ml/min/1.73 m 2 ). 46 Overall, these results demonstrate that canagliflozin provides clinically useful efficacy in patients with moderate renal impairment. While phase III studies of canagliflozin included patients with egfr between 30 and 45 ml/ min/1.73 m 2, canagliflozin is not recommended for these patients. In the United States, canagliflozin 100 mg can be initiated in patients with egfr 45 ml/min/1.73 m 2. In Europe, patients must have baseline egfr 60 ml/min/1.73 m 2 to initiate canagliflozin treatment; however, patients can continue treatment with canagliflozin 100 mg if egfr falls persistently to <60 ml/min/1.73 m Reductions in body weight In addition to the observed glycemic improvements, treatment with canagliflozin has been shown to provide statistically significant reductions in body weight relative to placebo. Weight loss with canagliflozin was dose related and generally consistent across the phase III studies (Fig. 5C) The observed reductions in body weight were sustained over 104 weeks with canagliflozin as add-on to metformin, compared with small increases seen with glimepiride (Fig. 6B). 37 Results of body composition analyses using dualenergy X-ray absorptiometry in two of the phase III studies (DIA3009, DIA3010) demonstrated that the body weight reduction seen with canagliflozin was attributable to a greater decrease in body fat mass ( 2/3) relative to lean body mass. 34,48 Importantly, the fat loss observed was both visceral and subcutaneous, with slightly greater visceral fat loss observed. BP-lowering effects Patients with T2DM commonly have hypertension, contributing to the increased risk that these patients have for both CV and microvascular complications. Reductions in systolic BP were observed with canagliflozin across phase III studies that were generally statistically significantly greater for both canagliflozin doses compared with placebo or active comparator (Fig. 5D) Canagliflozin treatment was also associated with consistent reductions in diastolic BP across the phase III studies. Importantly, canagliflozin had no meaningful effect on pulse. Effects on beta-cell function Canagliflozin was associated with improvements in fasting measures of beta-cell function (i.e., homeostatic model assessment of beta-cell function (HOMA2-%B) and proinsulin/c-peptide ratio). 39,40,42 In patients given a mixed-meal tolerance test, dose-related increases in the C-peptide area under the curve (AUC C ) to glucose area under the curve (AUC G ) were seen with canagliflozin compared with placebo or sitagliptin, suggesting an increase in insulin secretion relative to glucose with canagliflozin. 39,40,42 Improvements in beta-cell glucose sensitivity and the insulin secretion rate at specified plasma glucose concentrations were also observed with canagliflozin treatment. 49 Representative beta-cell function data for the placebocontrolled add-on to metformin plus sulfonylurea study are shown in Figure 7. The improvements in beta-cell function associated with canagliflozin treatment suggest that canagliflozin may slow T2DM progression, although longer studies are needed to assess the impact of sustained treatment on disease progression. 36 Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences
10 Rosenthal et al. Canagliflozin for the treatment of type 2 diabetes Figure 7. Effects on beta-cell function: (A) changes in HOMA2-%B and (B) ISR per plasma glucose values in the PBOcontrolled add-on to metformin plus sulfonylurea study (DIA3002) at week ,49 HOMA, homeostatic model assessment; ISR, insulin secretion rate; PBO, placebo; CANA, canagliflozin; LS, least squares; SE, standard error. Data in panel A are LS mean change (±SE) from baseline, and data in panel B are mean change (±SE) from baseline. Figure 7B adapted from Diabetologia 57(5): (2014) under the terms of the Creative Commons Attribution License, commons.org/licenses/by-nc-nd/3.0/. Overall safety and tolerability Across phase III trials, canagliflozin was generally well tolerated (Table 1) ,50,51 The incidence of discontinuations due to adverse events (AEs) was low overall, but slightly higher with canagliflozin compared with control due to an increased incidence of specific AEs likely related to canagliflozin s mechanism of action. The incidence of serious AEs was similar across treatment groups in all studies. Specific AEs associated with canagliflozin treatment include genital mycotic infections in both men and women, urinary tract infections (UTIs), and AEs related to osmotic diuresis and volume depletion. Genital mycotic infections with canagliflozin were generally mild or moderate in intensity, were often self-treated, responded to standard antifungal therapies in expected time frames, and led to few discontinuations across studies. 50,52 Among canagliflozin-treated females, an increased risk of genital mycotic infections was most prominent in those who had a prior history of vulvovaginitis. Among canagliflozintreated males, genital mycotic infections were more common in those who had a history of balanitis/balanoposthitis and were not circumcised. A modest increase in the incidence of AEs of Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences 37
11 Canagliflozin for the treatment of type 2 diabetes Rosenthal et al. UTI was observed with canagliflozin relative to control. 50,53 UTIs were generally mild or moderate in intensity, clinically manageable, and rarely associated with study discontinuation. Canagliflozin was not associated with increased rates of upper UTIs or serious UTIs. Canagliflozin was associated with an increase in osmotic diuresis related AEs (e.g., pollakiuria, polyuria, and thirst) that were generally mild or moderate in intensity and infrequently led to discontinuation. 50,54 Small mean percent changes in serum electrolytes were seen with canagliflozin treatment; elevations in serum potassium occurred with canagliflozin 300 mg, more frequently in patients with reduced egfr. 55 AEs associated with changes in serum electrolytes were low across treatment groups. Increases in hemoglobin and hematocrit were seen with canagliflozin that were likely the result of hemoconcentration associated with the osmotic diuretic effects of canagliflozin; these increases were generally not reported as AEs. 50 The incidence of AEs associated with reduced intravascular volume (e.g., hypotension, postural dizziness, orthostatic hypotension) was low across treatment groups. A higher incidence of AEs related to volume depletion was seen with canagliflozin 300 mg compared with canagliflozin 100 mg and placebo during the first 18 weeks of treatment, after which differences between the groups narrowed. 50 All AEs related to volume depletion with canagliflozin were considered mild to moderate in intensity; discontinuations due to volume depletion AEs and serious volume depletion AEs were similar across groups. 47 Higher incidences of volume depletion AEs were observed in patients 75 years of age, in patients with moderate renal impairment, and in patients taking loop diuretics; however, these factors did not increase the risk of serious AEs or discontinuations. Since the maximal canagliflozin-induced RT G level is above the threshold for hypoglycemia (70 mg/dl) and UGE is minimal when plasma glucose concentrations are below the RT G, the risk of hypoglycemia with canagliflozin is expected to be low. Across phase III studies, the incidence of documented hypoglycemia episodes was generally low in patients who were not on background AHA therapy associated with an increased risk of hypoglycemia. 50 In patients on background AHAs associated with an increased hypoglycemia risk (i.e., insulin or a sulfonylurea), an expected increase in hypoglycemia episodes was observed across treatment groups, with a moderately higher incidence seen with canagliflozin compared with placebo, and a similar incidence with canagliflozin relative to sitagliptin, despite the greater lowering of HbA 1c with canagliflozin versus sitagliptin. Effects on fasting plasma lipids Increases in high-density lipoprotein cholesterol (HDL-C) were observed with canagliflozin in all phase III studies; in the pooled placebocontrolled studies, increases of 5.4% and 6.3% were seen with canagliflozin 100 and 300 mg versus placebo, respectively, at week Numerically larger reductions in fasting triglycerides were seen with canagliflozin doses compared with placebo in most of the phase III studies, but the treatment difference was generally not statistically significant for individual studies; placebosubtracted reductions of 5.2% and 7.6% with canagliflozin 100 and 300 mg, respectively, were observed in the pooled placebo-controlled studiesatweek Increases in low-density lipoprotein cholesterol (LDL-C) were observed across the phase III studies; in the pooled placebocontrolled studies, placebo-subtracted increases of 4.5% and 8.0% were seen with canagliflozin 100 and 300 mg, respectively, at week Relative to LDL-C, smaller increases in non HDL-C were seen across studies In studies in which percentage increases in apolipoprotein B and LDL-C particle number (measured by nuclear magnetic resonance spectroscopy) were assessed, changes from baseline were typically about half as large as the increases in LDL-C. 36,40,56 The mechanism for the increase in LDL-C and HDL-C with canagliflozin is not known. These effects may be related to hemoconcentration resulting from the mild osmotic diuretic effects of canagliflozin and/or downstream metabolic effects of increasing UGE (e.g., shift in energy substrate utilization affecting hepatic triglyceride levels). The impact of canagliflozin treatment, including changes in lipids, on CV risk is being assessed as part of the long-term CANagliflozin CardioVascular Assessment Study (CANVAS) 57 and CANVAS-R (renal endpoints). The initial CV meta-analysis based on CANVAS as part of a cross-program metaanalysis confirmed the lack of a signal for an increase in the CV hazard ratio (based on major adverse CV 38 Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences
12 Rosenthal et al. Canagliflozin for the treatment of type 2 diabetes Table 1. Safety findings from the phase III program 51 Parameter CANA 32,34,36,39,40,42,44,47,55 Overall safety and tolerability Genital mycotic infections UTIs Osmotic diuresis related AEs (e.g., pollakiuria, polyuria, thirst) Volume depletion related AEs (e.g., orthostatic hypotension, dizziness postural) Hypoglycemia Fasting plasma lipids Clinical laboratory parameters Safety in special populations Patients with moderate renal impairment Older patients Generally well tolerated, with low incidences of serious AEs and AEs leading to study discontinuation Higher incidence versus PBO, SITA, and GLIM Few events led to study discontinuation Generally mild or moderate in intensity and responded to standard treatments Higher risk in patients with prior genital mycotic infection and in uncircumcised males Low recurrence rate in women and men Higher incidence versus PBO and GLIM, and similar incidence versus SITA Generally mild or moderate in intensity Not associated with upper UTIs or serious UTIs and few led to study discontinuation Incidence generally low, but higher than with PBO and SITA Few events led to study discontinuation Incidence generally low, dose dependent Few events led to study discontinuation Increased risk in patients aged 75 years, patients with moderate renal impairment, and patients taking loop diuretics Low incidence, similar to that with PBO, as monotherapy Significantly lower incidence versus GLIM, similar low incidence versus SITA as add-on to MET Incidence similar to that with SITA as add-on to MET + SU, despite greater HbA1c improvement seen with CANA Increases in HDL-C Increases in LDL-C and smaller increases in non HDL-C Decreases in triglycerides Moderate increases in blood urea nitrogen Small decreases in egfr with nadir observed early in treatment and values trending toward baseline for duration of study; commensurate increases in serum creatinine Moderate reductions in alanine aminotransferase and gamma glutamyl transferase, and moderate increases in bilirubin Small increases in hemoglobin Moderate reduction in serum urate Small changes in serum electrolytes (potassium, sodium, magnesium, bicarbonate, phosphate, calcium) Similar AE rates versus PBO Slightly higher incidences of UTIs (8% with CANA 300 mg versus 6% with both CANA 100 mg and PBO) Low incidence of AEs related to osmotic diuresis and volume depletion that was slightly higher with CANA versus PBO Transient reductions in egfr that were largest at week 3 and attenuated toward baseline over time ( 9.1%, 10.1%, and 4.5% with CANA 100 and 300 mg and PBO, respectively, at week 26) Median percent reductions in ACR versus PBO (approximately 30%, 21%, and 8% with CANA 100 and 300 mg and PBO, respectively, at week 26) Transient elevations in serum potassium with CANA 300 mg Safety profile in patients aged 65 years and 75 years consistent with other studies Higher risk of AEs related to volume depletion (e.g., postural dizziness, orthostatic hypotension, hypotension) in patients aged 75 years CANA, canagliflozin; AE, adverse event; PBO, placebo; SITA, sitagliptin; GLIM, glimepiride; UTI, urinary tract infection; MET, metformin; SU, sulfonylurea; HbA 1c, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; egfr, estimated glomerular filtration rate; ACR, albumin creatinine ratio. Adapted from Brunton S and Reid TS. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes. Hosp. Pract. 42(3): (2014) with permission from Taylor & Francis Ltd. Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences 39
13 Canagliflozin for the treatment of type 2 diabetes Rosenthal et al. events plus hospitalized unstable angina), with the upper bound of the 95% confidence interval (CI) <1.8. A subsequent planned CV meta-analysis to rule out an upper bound of the 95% CI of 1.3 will provide further information on the CV safety of canagliflozin. Renal safety Across studies, including those in patients with moderate renal impairment, canagliflozin treatment was generally associated with early reductions in egfr that trended back toward baseline over the treatment period Reductions in egfr were reversible after treatment discontinuation. 58 Representative data from the 104-week study of canagliflozin versus glimepiride as add-on to metformin demonstrated no meaningful effect of canagliflozin treatment on egfr over time (Fig. 6C). 37 In studies in which urinary albuminto-creatinine ratio (ACR) was assessed, reductions from baseline were observed with canagliflozin in patients with baseline albuminuria; no changes in urinary ACR were seen in normoalbuminuric patients. 34,37,38,43,44 In CANVAS and in the DIA3004 study of patients with moderate renal impairment, a smaller proportion of patients in the canagliflozin 100 and 300 mg groups relative to the placebo group progressed from normo- to microalbuminuria or micro- to macroalbuminuria at week ,43 In patients with moderate renal impairment, the incidence of renal-related AEs (e.g., GFR decreased, blood creatinine increased, renal failure) was higher with canagliflozin 100 and 300 mg compared with placebo; rates of serious renal-related AEs were low and similar across groups. 46 The increased incidence of renal-related AEs likely reflects the early, reversible reductions in egfr seen with canagliflozin treatment. In the pooled placebo-controlled studies, the incidence of renal-related AEs was low overall, but higher with canagliflozin 300 mg versus canagliflozin 100 mg and placebo, with one serious renal-related AE reported with canagliflozin 100 mg. 50 Fractures In the pooled placebo-controlled studies, the incidence of fractures with canagliflozin 100 and 300 mg and placebo was 0.7%, 0.6%, and 0.3%, respectively, over 26 weeks. 47 Among patients with T2DM not enrolled in CANVAS, the incidence of fractures was similar with canagliflozin and placebo or active comparator. 47 In CANVAS, the incidence rates of fractures were 1.6, 1.6, and 1.1 per 100 patientyears of exposure with canagliflozin 100 and 300 mg and placebo, respectively; most fractures occurred within the first 26 weeks of treatment. 47 Astudy assessing the effects of canagliflozin on bone health in patients with T2DM found that canagliflozin did not adversely affect bone mineral density over 104 weeks. 47 Conclusions The comprehensive results of a large phase III clinical development program demonstrate that canagliflozin 100 and 300 mg provide substantial and sustained reductions in HbA 1c, with additional potentially valuable clinical benefits on BP and body weight, and with a well-defined safety and tolerability profile that supports the use across a broad population of patients with T2DM. Care should be taken with patients that may be vulnerable to the volumedepletion effects of canagliflozin (i.e., patients aged 75 years, patients with moderate renal impairment, and those taking loop diuretics). Findings from ongoing studies will help further define the effects of canagliflozin on CV outcomes, as well as the impact of canagliflozin on micro- and macrovascular complications in patients with T2DM. Future directions Diabetic nephropathy is one of the microvascular complications of diabetes and is characterized by persistent albuminuria and a progressive decline in renal function. Hyperglycemia and renal hyperfiltration are important contributors to the onset and progression of diabetic nephropathy. In phase III studies, canagliflozin treatment was associated with an early decrease in egfr and a reduction in albuminuria when studied in the presence of angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs). These findings are not unlike the reduction in albuminuria and the early reduction in egfr seen with ACE inhibitor and ARB therapy in patients with diabetic nephropathy, for whom these agents act by vasodilating the efferent arteriole and reducing intraglomerular pressure. 59 A recently initiated 5-year renal outcomes trial (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation Trial; CREDENCE) is intended to determine whether canagliflozin has a renal protective 40 Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences
14 Rosenthal et al. Canagliflozin for the treatment of type 2 diabetes effect in patients with T2DM, stage 2 or 3 CKD, and macroalbuminuria, who are receiving standard of care and treatment with an ACE inhibitor or ARB. The renal-protective effect of canagliflozin relative to placebo will be assessed by the reduction in progression to end-stage kidney disease, doubling of serum creatinine, and renal or CV death. Obesity is a common comorbidity of T2DM. 4 The American Medical Association recently recognized obesity as a complex disease associated with comorbidities, including T2DM and CV disease. 60 The body weight reductions observed with canagliflozin treatment across phase III studies of patients with T2DM,aswellasinaphaseIIstudyofoverweight and obese individuals without diabetes, 61 suggest that canagliflozin may be an effective adjunctive treatment for obesity. Of note, the weight reduction associated with canagliflozin treatment across clinical studies is less than would be predicted based on observed UGE, with an increase in energy intake among patients treated with canagliflozin being one possible explanation for this finding. The weight loss provided by canagliflozin treatment has been shown to improve weight-related quality of life and satisfaction with physical and emotional health in patients with T2DM. 62 A phase II study of a fixed-dose combination of canagliflozin and the appetite suppressant phentermine is ongoing, with the expectation that phentermine may blunt any potential increase in food consumption associated with canagliflozin treatment. This combination of a centrally acting medication with an agent acting on a peripheral target represents a novel strategy for obesity treatment. Canagliflozin is not indicated for use in patients with type 1 diabetes mellitus (T1DM); however, due to its insulin-independent mechanism of action, canagliflozin may have potential use in the treatment of T1DM. Canagliflozin treatment may allow some patients with T1DM to reach glycemic goals with a reduced risk of hypoglycemia and a lower total insulin dose. The weight loss benefits of canagliflozin could also be important for these patients as a part of diabetes management. Of note, canagliflozin is not recommended for the treatment of diabetic ketoacidosis. A phase II clinical trial is currently underway to evaluate the efficacy and safety of canagliflozin in patients with T1DM. Given that canagliflozin treatment is associated with improvements in beta-cell function, canagliflozin could also potentially be used to reduce or delay the progression to T2DM in patients with prediabetes. A reduction in the progression to T2DM could reduce or delay the onset of the long-term microvascular complications of diabetes. In summary, the SGLT2 inhibitor canagliflozin is an important innovation for patients with T2DM and has the potential to not only help patients improve glycemic control, but also reduce body weight and BP. As it gains additional approvals in different countries and is studied in other T2DM patient populations, canagliflozin will provide a new treatment option for increasing numbers of patients with T2DM worldwide. Acknowledgments This invited review article was sponsored by Janssen Global Services, LLC. Editorial assistance was provided to the authors by Kimberly Fuller, PhD, of MedErgy, and was funded by Janssen Global Services, LLC. The authors were involved at all stages of manuscript development and maintained full control over the scientific content. Conflicts of interest All authors are full-time employees of Janssen Research & Development, LLC. References 1. Centers for Disease Control and Prevention National Diabetes Fact Sheet. Accessed February 7, Ali, M.K., K. McKeever Bullard, G. Imperatore, et al Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes national health and nutrition examination survey, United States, MMWR Morb. Mortal. Wkly. Rep. 61: Clark, C.M., Jr The burden of chronic hyperglycemia. Diabetes Care 21(Suppl 3): C32 C Inzucchi, S.E., R.M. Bergenstal, J.B. Buse, et al Management of hyperglycemia in type 2 diabetes, 2015: a patientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38: Bennett, W.L., N.M. Maruthur, S. Singh, et al Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann. Intern. Med. 154: Gross, J.L., C.K. Kramer, C.B. Leitao, et al Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann. Intern. Med. 154: Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences 41
15 Canagliflozin for the treatment of type 2 diabetes Rosenthal et al. 7. American Diabetes Association Standards of medical care in diabetes Diabetes Care 35: S11 S Cook, M.N., C.J. Girman, P.P. Stein, et al Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet. Med. 24: Cook, M.N., C.J. Girman, P.P. Stein, et al Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28: Bakris, G.L., V.A. Fonseca, K. Sharma, et al Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 75: Chao, E.C. & R.R. Henry SGLT2 inhibition a novel strategy for diabetes treatment. Nat. Rev. Drug. Discov. 9: Bailey, C.J Renal glucose reabsorption inhibitors to treat diabetes.trends Pharmacol. Sci. 32: Bays, H From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr. Med. Res. Opin. 25: Rahmoune, H., P.W. Thompson, J.M. Ward, et al Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: Defronzo, R.A Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: Gilbert, R.E Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int. 86: Haas, B., N. Eckstein, V. Pfeifer, et al Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr. Diabetes 4: e Wilding, J.P The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 63: Ehrenkranz, J.R., N.G. Lewis, C.R. Kahn, et al Phlorizin: a review. Diabetes Metab. Res. Rev. 21: Rossetti, L., D. Smith, G.I. Shulman, et al Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79: Defronzo, R.A., J.A. Davidson & S. Del Prato The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14: Devineni, D., J. Murphy, S.-S. Wang, et al Absolute oral bioavailability and pharmacokinetics of canagliflozin: a microdose study in healthy participants. Clin Pharmacol. Drug. Dev. 4: INVOKANA R (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals; Mamidi, R.N., F. Cuyckens, J. Chen, et al Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug. Metab. Dispos. 42: Devineni, D., C.R. Curtin, D. Polidori, et al Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol. 53: Sha, S., D. Devineni, A. Ghosh, et al Pharmacodynamic effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 9: e Devineni, D., N. Vaccaro, D. Polidori, et al Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose cotransporter 2, in healthy participants. Int. J. Clin. Pharmacol. Ther. 53: Sha, S., D. Devineni, A. Ghosh, et al Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes. Metab. 13: Devineni, D., L. Morrow, M. Hompesch, et al Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes. Metab. 14: Wright, E.M Renal Na(+)-glucose cotransporters. Am.J.Physiol.Renal.Physiol.280: F10 F Polidori, D., S. Sha, S. Mudaliar, et al Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36: Bode, B., K. Stenlöf, D. Sullivan, et al Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp. Pract. 41: Bode,B., K.Stenlöf,S. Harris,et al Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes. Metab. 17: Cefalu, W.T., L.A. Leiter, K.-H. Yoon, et al Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: Forst, T., R. Guthrie, R. Goldenberg, et al Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes. Metab. 16: Lavalle-González, F.J., A. Januszewicz, J. Davidson, et al Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56: Leiter, L.A., K.-H. Yoon, P. Arias, et al Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care 38: Neal, B., V. Perkovic, D. de Zeeuw, et al Efficacy and safety of canagliflozin, an inhibitor of sodium glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 38: Schernthaner, G., J.L. Gross, J. Rosenstock, et al Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control 42 Ann. N.Y. Acad. Sci (2015) C 2015 The Authors. Annals of the New York Academy of Sciences
1. Pharmacokinetics. When is steady state achieved? Steady-state was reached after 4 to 5 days of once-daily dosing with Sulisent 100 mg to 300mg.
1. Pharmacokinetics How is Sulisent metabolized? Sulisent has a novel mechanism of action that targets the kidneys and allows for excess glucose excretion resulting in urinary calorie loss. Sulisent is
More informationFixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
Adv Ther (2017) 34:41 59 DOI 10.1007/s12325-016-0434-2 REVIEW Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview Jaime A. Davidson. Lance Sloan Received:
More informationThe Journal of Clinical Hypertension Vol 16 No 12 December
ORIGINAL PAPER Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus Matthew R. Weir, MD; 1
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationStudy Duration (Weeks) Reference Number
Supplementary Table 1. SGLT2 Inhibitor Monotherapy SGLT2 Inhibitor vs /Comparator Canagliflozin 100 mg Canagliflozin 300 mg 26 26 (n) 195 197 in 0.91 1.16 in FPG 36.0 43.2 Canagliflozin 100 mg Canagliflozin
More informationSodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview Juan F. Mosley II, PharmD, CPh, AAHIVP; Lillian Smith, PharmD, CPh, MBA; Emily Everton,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationSITA 100 mg (n = 378)
Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)
More informationShort-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting
Singapore Med J 2018; 59(5): 251-256 https://doi.org/10.11622/smedj.2017095 Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationSGLT-2 Inhibition in the Kidney: Changing Paradigms in the Treatment of Type 2 Diabetes Mellitus
A promotional supplement sponsored by: A supplement to www.pcmg-us.org INDUSTRY DIRECT SGLT-2 Inhibition in the Kidney: Changing Paradigms in the Treatment of Type 2 Diabetes Mellitus FACULTY Eden M. Miller,
More informationRenal effects of canagliflozin in type 2 diabetes mellitus
Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: https://www.tandfonline.com/loi/icmo20 Renal effects of canagliflozin in type 2 diabetes mellitus Vlado
More informationEfficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Diabetes Ther (2015) 6:289 302 DOI 10.1007/s13300-015-0117-z ORIGINAL RESEARCH Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized,
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationSodium Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Touro College and University System Touro Scholar College of Osteopathic Medicine (TUC) Publications and Research College of Osteopathic Medicine 215 Sodium Glucose Co-Transporter 2 Inhibitors in the Treatment
More informationSGLT2 Inhibitors. Vijay Negalur
C H A P T E R 173 SGLT2 Inhibitors Vijay Negalur INTRODUCTION Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by hyperglycemia that results from insulin resistance, diminished
More informationAmbrish Mithal MD, DM
Ambrish Mithal MD, DM Chairman, Division of Endocrinology and Diabetes Medanta The Medicity Padma Bhushan Awardee 2015, Member Governing Council, Indian Council of Medical Research (ICMR) Dr Mithal is
More informationLabeled Uses: Indicated as a treatment of type 2 diabetes in adjunct with diet and exercise. Unlabeled Uses: No unlabeled uses have been indicated.
Brand Name: Steglatro Generic Name: ertugliflozin Manufacturer 1,5 : Merck Sharp & Dohme Corp. Drug Class 1,2,3,4,5 : Antidiabetic Agent, SGLT-2 inhibitor Uses 1,2,3,4,5 : Labeled Uses: Indicated as a
More informationUK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1
PRESS RELEASE 24 th February, 2014 UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1 London, 24 February 2014
More informationBrand name: Steglatro. Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck
Brand name: Steglatro Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck Drug Class: Sodium-glucose co-transporter 2 (SGLT2) inhibitor Uses: Labeled: Indicated as adjunct to diet and
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationDiabetes is a chronic disease associated with a variety
n REPORTS n Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin Robert A. Bailey, MD; C. V. Damaraju, PhD; Silas C. Martin, MS; Gary E. Meininger, MD; Marcia F. T. Rupnow,
More informationCost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
More informationIl blocco del cotrasportatore. della terapia antiiperglicemica. Anna Solini
Il blocco del cotrasportatore sodioglucosio come target della terapia antiiperglicemica Anna Solini Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell Area Critica Università di Pisa Grant
More informationPRODUCT MONOGRAPH INVOKANA. canagliflozin tablets. 100 mg and 300 mg as anhydrous canagliflozin
PRODUCT MONOGRAPH Pr canagliflozin tablets 100 mg and 300 mg as anhydrous canagliflozin ATC Code: A10BK02 Other blood glucose lowering drugs, excl. insulins Janssen Inc. 19 Green Belt Drive Toronto, Ontario
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationPRODUCT MONOGRAPH INVOKANA. canagliflozin tablets. 100 mg and 300 mg as anhydrous canagliflozin
PRODUCT MONOGRAPH Pr canagliflozin tablets 100 mg and 300 mg as anhydrous canagliflozin ATC Code: A10BK02 Other blood glucose lowering drugs, excl. insulins Janssen Inc. 19 Green Belt Drive Toronto, Ontario
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationPRODUCT MONOGRAPH FORXIGA
PRODUCT MONOGRAPH dapagliflozin tablets (as dapagliflozin propanediol monohydrate) 5 mg and 10 mg ATC Code: A10BK01 Sodium-glucose co-transporter 2 (SGLT2) inhibitors AstraZeneca Canada Inc. 1004 Middlegate
More informationStudy Design: Prospective, Multicenter randomized, parallel-group, double blind, placebo controlled study.
Brand Name: Farxiga Generic Name: Dapagliflozin Manufacturer: Astra-Zenica Drug Class 1,2 : Antidiabetic agent, SGLT2 Inhibitor Uses: Labeled Uses 1,2,3,4 : Improving glycemic control in adults with type
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationPharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study
original article Diabetes, Obesity and Metabolism 17: 188 197, 2015. 2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ORIGINAL ARTICLE Pharmacodynamic differences
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationDiabetic Ketoacidosis and Related Events in the Canaglif lozin Type 2 Diabetes Clinical Program Diabetes Care 2015;38: DOI: 10.
1680 Diabetes Care Volume 38, September 2015 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL Diabetic Ketoacidosis and Related Events in the Canaglif lozin Type 2 Diabetes Clinical Program Diabetes Care 2015;38:1680
More informationJARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.
JARDIAMET (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg NAME OF THE MEDICINE JARDIAMET contains two oral antihyperglycaemic
More informationINVOKANA. canagliflozin hemihydrate NEW ZEALAND DATA SHEET
INVOKANA canagliflozin hemihydrate NEW ZEALAND DATA SHEET 1. PRODUCT NAME INVOKANA 100 mg film coated tablets INVOKANA 300 mg film coated tablets 2. QUALTITATIVE AND QUANTITATIVE COMPOSITION INVOKANA is
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationCanagliflozin for Type 2 diabetes: an up-to-date evidence summary
Diabetes Management Canagliflozin for Type 2 diabetes: an up-to-date evidence summary Aris Liakos 1, Thomas Karagiannis 1, Eleni Bekiari 1 & Apostolos Tsapas*,1,2 Practice points Canagliflozin is a sodium-glucose
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationDespite the irrefutable evidence for the important
PERSPECTIVES IN DIABETES Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30 50% of Filtered Glucose Load in Humans Muhammad A. Abdul-Ghani, Ralph A. DeFronzo, and Luke Norton Inhibitors of
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Invokana 100 mg film-coated tablets Invokana 300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Invokana
More informationCanagliflozin, a New Sodium-Glucose Co- Transporter 2 Inhibitor, in the Treatment of Diabetes
Butler University Digital Commons @ Butler University Scholarship and Professional Work COPHS College of Pharmacy & Health Sciences 2013 Canagliflozin, a New Sodium-Glucose Co- Transporter 2 Inhibitor,
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationOriginal Article Therapeutic effect of canagliflozin on type 2 diabetes mellitus: a systematic review and meta-analysis
Int J Clin Exp Med 2016;9(5):7807-7817 www.ijcem.com /ISSN:1940-5901/IJCEM0018493 Original Article Therapeutic effect of canagliflozin on type 2 diabetes mellitus: a systematic review and meta-analysis
More informationROLE OF KIDNEY AND SGLT-2 INHIBITOR IN GLUCOSE HOMEOSTASIS
ROLE OF KIDNEY AND SGLT-2 INHIBITOR IN GLUCOSE HOMEOSTASIS Prof. Dato Dr. Mafauzy Mohamed Professor of Medicine / Senior Consultant Endocrinologist Health Campus, UniversiB Sains Malaysia The Kidneys Maintain
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationInitial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes
Diabetes Care 1 Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes DOI: 10.2337/dc15-1736 Julio Rosenstock, 1 Leonard Chuck,
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationINVOKANA (canagliflozin) tablets, for oral use
(canagliflozin) tablets, for oral use Revised: 07/2017 076265-170714 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.19 Subject: SGLT2 Inhibitors Page: 1 of 5 Last Review Date: December 3, 2015 SGLT2 Inhibitors Description
More informationIs an SGLT2 inhibitor right for your patient with type 2 diabetes?
Is an SGLT2 inhibitor right for your patient with type 2 diabetes? Metformin isn t quite doing the job or is contraindicated? Here s a look at the patients who may benefit from these agents and the monitoring
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationNEW TREATMENT OPTIONS IN INDIVIDUALIZED TYPE 2 DIABETES MELLITUS MANAGEMENT TARGETING THE KIDNEY TO REDUCE HYPERGLYCAEMIA
NEW TREATMENT OPTIONS IN INDIVIDUALIZED TYPE 2 DIABETES MELLITUS MANAGEMENT TARGETING THE KIDNEY TO REDUCE HYPERGLYCAEMIA Richard Yazbeck, MD Endocrinologist Lebanese Hospital (Geitaoui) 11/26/2016 Disclosures:
More informationThe Emerging Role of the Kidney and SGLT2 Inhibition for Patients with Type 2 Diabetes
Silvio E. Inzucchi, MD The Emerging Role of the Kidney and SGLT2 Inhibition for Patients with Type 2 Diabetes Professor of Medicine Clinical Director Section of Endocrinology Yale University New Haven,
More informationEfficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
Sinclair et al. BMC Endocrine Disorders 2014, 14:37 RESEARCH ARTICLE Open Access Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis
More informationPharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
Pharmacokinetics and Pharmacodynamics Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus The Journal of Clinical
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationSee accompanying articles, pp. 352, 365, 373, 376, 384, 394, 403, 412, 420, 429, and 431.
Diabetes Care Volume 38, March 2015 355 Canaglif lozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin:
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationInternational Diabetes Federation
40 Original Article A Prospective Analysis of the Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors: Real World Evidence from Clinical Practice in India Bhavana Sosale 1, Aravind R Sosale
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationCanagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationTaking Translation into the Clinic: Can We Improve the Probability of Success?
Taking Translation into the Clinic: Can We Improve the Probability of Success? Janssen R&D/Cardiovascular & Metabolism Therapeutic Area Nicholas Di Prospero, MD, PhD Translational Medicine Group Disclaimer:
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationDesign: This was an open-label study with 2 sequential parts. Setting: The study was performed at a single center in Germany.
JCEM ONLINE Brief Report Endocrine Care Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationHyperglycemia: Type I Diabetes Mellitus
296 PHYSIOLOGY CASES AND PROBLEMS Case 53 Hyperglycemia: Type I Diabetes Mellitus David Mandel was diagnosed with type I (insulin-dependent) diabetes mellitus when he was 12 years old (see Cases 30 and
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationAUSTRALIAN PRODUCT INFORMATION - JARDIANCE empagliflozin film-coated tablets
AUSTRALIAN PRODUCT INFORMATION - JARDIANCE empagliflozin film-coated tablets 1 NAME OF THE MEDICINE empagliflozin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION JARDIANCE 10 mg film-coated tablets contains
More informationINVOKANA PRODUCT INFORMATION
INVOKANA PRODUCT INFORMATION NAME OF THE MEDICINE Canagliflozin The chemical name is (1S) 1,5 anhydro 1 [3 [[5 (4 fluorophenyl) 2 thienyl]methyl] 4 methylphenyl] Dglucitol present in the tablets as the
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationFaculty Affiliation. Faculty Disclosures. Learning Objectives. Prevalence and Burden of Diabetes in the United States
Faculty Affiliation Combined Targeted Approaches for the Treatment of Type 2 Diabetes: The Role of the Kidney Mark Stolar, MD Associate Professor of Clinical Medicine Division of General Internal Medicine
More informationBrand Name: Farxiga. Generic Name: dapagliflozin. Manufacturer 1 : Bristol-Myers Squibb
Brand Name: Farxiga Generic Name: dapagliflozin Manufacturer 1 : Bristol-Myers Squibb Drug Class 1,3,4 : Antidiabetic, sodium-glucose cotransporter 2 (SGLT2) inhibitor Uses Labeled Uses 1,2,3,4,5 : Adjunct
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationInnovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors. April 3 rd, 2014
Innovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors April 3 rd, 2014 KM Pantalone Associate Staff Endocrinology Speaker Bureau: Disclosures Bristol-Myers
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More information